Physician profile
Robert C Slaton
NPI 1578557096
$12,574.91
in general payments reported to CMS, 2019-2025
44 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $1,182 · 2021: $1,969 · 2022: $2,235 · 2023: $1,832 · 2024: $2,470 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,168.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,057.12 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,403.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,257.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,206.33 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,045.27 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $504.43 | 2019-2021 | |
| Abbvie INC. | $459.67 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $419.49 | 2021-2024 | |
| Pfizer INC. | $419.11 | 2019-2025 | |
| Abbott Laboratories | $335.43 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $252.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $221.12 | 2020-2023 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $218.33 | 2021 | |
| Astellas Pharma US INC | $206.68 | 2019-2025 | Veozah |
| Radius Health, INC. | $189.66 | 2023-2025 | Tymlos |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Slaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.